A survey of pregnant women using isotretinoin

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 73, Issue 11, 2005, Pages 881-887

  Robertson, Julia ^a   Polifka, Janine E ^b   Avner, Marina ^c   Chambers, Christina ^d   Delevan, George ^a   Koren, Gideon ^c   Lavigne, Sharon Voyer ^e   Martinez, Lynn P ^a   Miller, Richard K ^f   Carey, John C ^g  

^a UTAH DEPARTMENT OF HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Accutane; Birth defects; Isotretinoin; Pregnancy

Indexed keywords

AMNESTEEM; ETRETIN; ISOTRETINOIN; ORATANE;

ACNE; ADULT; BIRTH CONTROL; BIRTH DEFECT; CLINICAL TRIAL; COGNITION; CONGENITAL HEART MALFORMATION; CONTRACEPTION; EMBRYOPATHY; FEMALE; FETUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MICROGNATHIA; MULTICENTER STUDY; PATIENT INFORMATION; PREGNANCY COMPLICATION; PREGNANCY TEST; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REVIEW; TERATOGENICITY; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ADULT; CONTRACEPTION; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; PREGNANCY; PREGNANCY TESTS; QUESTIONNAIRES; TERATOGENS;

EID: 28444438101     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20197     Document Type: Review

References (27)

1. Adams J, Lammer EJ. 1991. Relationship between dysmorphology and neuropsychological function in children exposed to isotretinoin "in utero". In: Fujii T, Boer GJ, editors. Functional neuroteratology of short term exposure to drugs. Tokyo: Teikyo University Press, pp. 159-170.
2. Atanackovic G, Koren G. 1999. Fetal exposure to isotretinoin: failure to comply with the Pregnancy Prevention Program. CMAJ 160:1719-1720.
3. Brinker A, Trontell A, Beitz J. 2002. Pregnancy and pregnancy rates in association with isotretinoin (Accutane). J Am Acad Dermatol 47:798-799.
4. Carver V, Coyle B, Koren G, et al. 2001. A call for action: prevention of fetal exposure to isotretinoin. A position paper by the Organization of Teratology Information Services public affairs committee. Reprod Toxicol 15:729.
5. Cooper AJ. 2003. Australian Roaccutane Advisory Board. Treatment of acne with isotretinoin: recommendations based on Australian experience. Aust J Dermatol 44:97-105.
6. Dai WS, LaBraico JM, Stern RS. 1992. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 26:599-606.
7. Doering PL, Araujo OE, Frohnaple DJ, et al. 1992. Patterns of prescribing isotretinoin: focus on women of childbearing potential. Ann Pharmacother 26:155-161.
8. Goldsmith LA, Bolognia JL, Callen JP, et al. 2004. American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 50:900-906.
9. Henshaw SK. 1998. Unintended pregnancy in the United States. Fam Plann Perspect 30:24-29.
10. Hermes B, Praetel C, Henz BM. 1998. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol 11:117-121.
11. Honein MA, Paulozii LJ, Erickson JD. 2001. Continued occurrence of Accutane-exposed pregnancies. Teratology 64:142-147.
12. Honein MA, Moore CA, Erickson JD. 2004. Can we ensure the safe use of known teratogens? Drug Saf 27:1069-1080.
13. Jones KL, Adams J, Chambers CD, et al. 2001. Isotretinoin and pregnancy [Letter]. JAMA 285:2079-2080.
14. Koren G, Avner A, Shear N. 2004. Generic isotretinoin: a new risk for unborn children. CMAJ 170:1567-1568.
15. Lammer EJ, Chen DT, Hoar RM, et al. 1985. Retinoic acid embryopathy. N Engl J Med 313:837-841.
16. Lammer EJ, Hayes EM, Schunior A, Holmes LB. 1987. Risk for major malformation among human fetuses exposed to isotretinoin (13-cisretinoic acid). Teratology 35:68A.
17. Lavigne SV, Rosengren S. 2000. Prenatal accutane use: the ongoing challenge to prevent fetal exposure. Teratology 6:520-521.
18. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. 1993. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol 129:292-296.
19. Leen-Mitchell M, Martinez L, Gallegos S, et al, 2000. Mini-review: history of organized teratology information services in North America. Teratology 61:314-317.
20. Lowenstein EJ. 2002. Isotretinoin made S.M.A.R.T. and simple. Cutis 70: 115-120.
21. Mitchell AA, Van Bennekom CM, Louik C. 1995. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 333:101-106.
22. O'Donnell J. 2003. Overview of existing research and information linking isotretinoin (Accutane), depression, psychosis, and suicide. Am J Ther 10:148-159.
23. Perry MD, McEvoy GK. 1983. Isotretinoin: new therapy for severe acne. Clin Pharm 2:12-19.
24. Robertson JA, Martinez LP, Gallegos S, et al. 2002. Accutane cases: a teratogen information service's approach [Letter]. Teratology 66:1-2.
25. Shahidullah M, Tham SN, Goh CL. 1994. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol 33:60-63.
26. Uhl K. 2004. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Drug Safety and Risk Management Advisory Committee, in Joint Session with the Dermatologic and Ophthalmic Drugs Advisory Committee. Proceedings of the FDA Joint Drug Safety and Risk Management and Dermatologic and Opthalmic Drugs Advisory Committee Meeting, Gaithersburg, MD, February 27, 2004. Available at: http://www.fda. gov/ohrms/dockets/ac/04/transcripts/4017T2.htm. Accessed: September 3, 2005.
27. Wysowski DK, Swann J, Vega A. 2002. Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J Am Acad Dermatol 46:505-509.